AR107883A1 - PROTEIN A BINDING POLIPEPTIDES, ANTI-EPHA2 ANTIBODIES AND METHODS OF USE OF THESE - Google Patents
PROTEIN A BINDING POLIPEPTIDES, ANTI-EPHA2 ANTIBODIES AND METHODS OF USE OF THESEInfo
- Publication number
- AR107883A1 AR107883A1 ARP170100644A ARP170100644A AR107883A1 AR 107883 A1 AR107883 A1 AR 107883A1 AR P170100644 A ARP170100644 A AR P170100644A AR P170100644 A ARP170100644 A AR P170100644A AR 107883 A1 AR107883 A1 AR 107883A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- acid sequence
- amino acid
- antibodies
- epha2
- Prior art date
Links
Abstract
Se proporcionan en la presente descripción anticuerpos (por ejemplo, scFv) que incluyen CDR y regiones de marco humanas que confieren propiedades sobre los anticuerpos. En determinadas modalidades, dichas propiedades incluyen termoestabilidad (por ejemplo un aumento en la temperatura de fusión), unión eficaz de la Proteína A de Staphylococcus aureus o ambas. En determinados aspectos, los anticuerpos son anticuerpos de internalización que se unen específicamente al antígeno EphA2 relacionado con el tumor. Reivindicación 1: Un anticuerpo de receptor 2 tipo A anti-Efrina (EphA2) que comprende: una VH que comprende: una CDR1 de VH que comprende la secuencia de aminoácidos SYAMH (SEQ ID Nº 17); una CDR2 de VH que comprende la siguiente secuencia de aminoácidos de 17 aminoácidos X¹⁷ISPX¹⁸GX¹⁹NX²⁰YYADSVKG (SEQ ID Nº 18), donde X¹⁷ es A o V; X¹⁸ es A, D, H, N, P, S o T; X¹⁹ es A, R, H, N o P; y X²⁰ es K o T; y una CDR3 de VH que comprende la secuencia de aminoácidos ASVGATGPFDI (SEQ ID Nº 19); y una VL que comprende: una CDR1 de VL que comprende la secuencia de aminoácidos QGDSLSYYAS (SEQ ID Nº 20); una CDR2 de VL que comprende la secuencia de aminoácidos GEENRPS (SEQ ID Nº 21); y una CDR3 de VL que comprende la secuencia de aminoácidos NSRDSSGTHLTV (SEQ ID Nº 22); donde el anticuerpo se une, de forma inmunoespecífica, al dominio extracelular de EphA2.Antibodies (eg scFv) that include CDRs and human framework regions that confer properties on the antibodies are provided herein. In certain embodiments, said properties include thermostability (for example an increase in melting temperature), effective binding of Staphylococcus aureus Protein A or both. In certain aspects, antibodies are internalization antibodies that specifically bind to the tumor-related EphA2 antigen. Claim 1: An anti-Ephrine type A receptor 2 antibody (EphA2) comprising: a VH comprising: a VH CDR1 comprising the amino acid sequence SYAMH (SEQ ID No. 17); a VH CDR2 comprising the following amino acid sequence of 17 amino acids X¹⁷ISPX¹⁸GX¹⁹NX²⁰YYADSVKG (SEQ ID No. 18), where X¹⁷ is A or V; X¹⁸ is A, D, H, N, P, S or T; X¹⁹ is A, R, H, N or P; and X²⁰ is K or T; and a VH CDR3 comprising the amino acid sequence ASVGATGPFDI (SEQ ID No. 19); and a VL comprising: a VL CDR1 comprising the amino acid sequence QGDSLSYYAS (SEQ ID No. 20); a VL CDR2 comprising the GEENRPS amino acid sequence (SEQ ID No. 21); and a VL CDR3 comprising the amino acid sequence NSRDSSGTHLTV (SEQ ID No. 22); where the antibody binds, immunospecifically, to the extracellular domain of EphA2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662309365P | 2016-03-16 | 2016-03-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR107883A1 true AR107883A1 (en) | 2018-06-13 |
Family
ID=62683537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170100644A AR107883A1 (en) | 2016-03-16 | 2017-03-15 | PROTEIN A BINDING POLIPEPTIDES, ANTI-EPHA2 ANTIBODIES AND METHODS OF USE OF THESE |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR107883A1 (en) |
-
2017
- 2017-03-15 AR ARP170100644A patent/AR107883A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200390T1 (en) | Monoclonal antibodies against human b cell maturation antigen (bcma) | |
| HRP20192098T1 (en) | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof | |
| CO2018013500A2 (en) | Anti-pd-l1 antibodies and uses thereof | |
| ES2776179T3 (en) | Antibodies directed against surface determinants of S. aureus | |
| HRP20201022T1 (en) | Fully human antibody against human cd137 and use thereof | |
| CL2021001686A1 (en) | Single Domain Antibody-Based Chimeric Antigen Receptors and Methods of Using Them (Divisional Application No. 201800378) | |
| RU2016100892A (en) | ANTIBODIES AGAINST TWEAKR AND THEIR APPLICATION | |
| PE20210377A1 (en) | ANTI-PD-L1 ANTIBODIES AND USES OF THEM | |
| JP2018520657A5 (en) | ||
| CL2019001756A1 (en) | Anti-cd73 antibodies and uses thereof. | |
| CO2019013614A2 (en) | Antigen-binding domain | |
| PE20231958A1 (en) | BINDING MOLECULES TO PD-1 AND METHODS OF USE THEREOF | |
| JP2014205674A5 (en) | ||
| JP2019535670A5 (en) | ||
| MY186351A (en) | Multispecific antibodies | |
| HRP20220891T1 (en) | Antibodies, uses&methods | |
| JP2015504421A5 (en) | ||
| PE20211887A1 (en) | ANTIGENIC CHIMERICAL RECEPTOR (CAR) THAT INCLUDES A DOMAIN OF BINDING TO ANTIGENS, WHICH SELECTIVELY JOINES THE CONSTANT REGION OF THE TCR BETA 1 (TRBC1) OR TRBC2 OF T CELLS | |
| JP2017504578A5 (en) | ||
| HRP20221088T1 (en) | Antibodies and methods of use | |
| CY1121158T1 (en) | ANTIBODY ABLE TO RECOGNIZE SPECIFIC TRANSFERRIN RECEPTORS | |
| HRP20201785T1 (en) | Multivalent and multispecific dr5-binding fusion proteins | |
| RS53327B (en) | A monoclonal antibody to cd44 for use in the treatment of head and neck squamous cell carcinoma | |
| JP2015509960A5 (en) | ||
| HRP20220069T1 (en) | Antibody |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |